Description
Mevastatin is an HMG-CoA reductase inhibitor that exhibits anti-hyperlipidemic, anticancer, and immunomodulatory activities. Mevastatin induces apoptosis and inhibits growth of salivary adenoid cystic carcinoma cells by increasing cytochrome c release, activation of caspase 3, and phosphorylation of JNK, p38 MAPK, and ERK1/2. In other models, mevastatin inhibits bisphosphonate-induced activation of γδ T cells and release of TNF-α.
References
Zhang S, Wang XL, Gan YH, et al. Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcinoma cells. Anticancer Drugs. 2010 Aug;21(7):678-86. PMID: 20629200.
Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004 Feb;19(2):278-88. PMID: 14969398.
Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976 Dec;29(12):1346-8. PMID: 1010803.
ABOUT LKT LABS
LKT Laboratories is a biochemical supply company focused on the synthesis, purification, and isolation of small molecules for research applications. Its range of products exhibit known biological activities that have found uses in a wide array of research fields, especially cancer and neuroscience. These products include protein kinase inhibitors, ion channel modulators, and activators. LKT serves the global research community by supplying the highest purity products for use in cell culture models, animal studies, or as reference materials or analytical standards.